血清钙卫蛋白（S100A8/A9）水平作为霍奇金淋巴瘤治疗反应的新潜在生物标志物。

Serum calprotectin (S100A8/A9) levels as a new potential biomarker of treatment response in Hodgkin lymphoma.

机构信息

Department of Hematology, Medical Faculty, University of Kocaeli, Kocaeli, Turkey.

Department of Hematology, Marmara University Hospital, Istanbul, Turkey.

出版信息

Int J Lab Hematol. 2021 Aug;43(4):638-644. doi: 10.1111/ijlh.13559. Epub 2021 Apr 27.

DOI:10.1111/ijlh.13559

PMID:33904653

Abstract

INTRODUCTION

Hodgkin lymphoma (HL) is unusual among malignancies, with inflammation playing such a prominent role in its pathogenesis. S100A8/A9 (calprotectin) is a heterodimeric protein, which has a role in the inflammatory response and oncogenesis. In this study in HL patients, the correlation between serum S100A8/A9 levels and treatment responses was investigated along with whether this marker is correlated with other inflammatory markers.

MATERIALS AND METHODS

Thirty-three HL patients and 20 healthy volunteers were included. Demographic and clinical characteristics were recorded. Calprotectin levels were measured with Human S100A8/A9 Heterodimer Quantikine ELISA kit. Calprotectin levels were measured twice in patients, before and after treatment, and once in the control group. Treatment responses were evaluated with positron emission tomography-computed tomography (PET-CT).

RESULTS

The mean age of patients was 44.3 ± 18.1 (66.3% male). The median (IQR) values of S100A8/A9 before and after treatment in the patient group were 4.98 (2.6-7.8) and 1.87 (1.1-4.8)µg/mL. Median (IQR) S100A8/A9 concentration in the control group was 1.41 (0.98-2.73)µg/mL. In patients, pretreatment values were significantly higher than in controls (P < .001). However, median values of patients after treatment and controls were similar. Patient median S100A8/A9 levels were significantly lower post-treatment compared with pretreatment values (P = .001). When inflammatory markers were examined within groups, no relationship was found between markers. In ROC analysis, a S100A8/A9 cutoff value of ≥3.31µg/mL accurately discriminated end-of-treatment PET positivity (AUC = 0.78; 95% CI 0.58-0.98; accuracy = 76.2%).

CONCLUSION

S100A8/A9 may be a potential biomarker for treatment response in HL independent of inflammation. This is the first study to investigate and show this finding. However, further large-scale studies are still required.

摘要

简介

霍奇金淋巴瘤（HL）在恶性肿瘤中较为特殊，其发病机制中炎症起着重要作用。S100A8/A9（钙卫蛋白）是一种异二聚体蛋白，在炎症反应和肿瘤发生中具有一定作用。本研究在 HL 患者中，研究了血清 S100A8/A9 水平与治疗反应之间的相关性，以及该标志物是否与其他炎症标志物相关。

材料与方法

纳入 33 例 HL 患者和 20 名健康志愿者。记录人口统计学和临床特征。采用 Human S100A8/A9 Heterodimer Quantikine ELISA 试剂盒检测钙卫蛋白水平。患者在治疗前后各检测 2 次，对照组检测 1 次。采用正电子发射断层扫描-计算机断层扫描（PET-CT）评估治疗反应。

结果

患者平均年龄为 44.3±18.1 岁（66.3%为男性）。治疗前和治疗后患者组 S100A8/A9 的中位数（IQR）值分别为 4.98（2.6-7.8）和 1.87（1.1-4.8）μg/mL。对照组 S100A8/A9 的中位数（IQR）浓度为 1.41（0.98-2.73）μg/mL。治疗前患者的 S100A8/A9 值明显高于对照组（P<.001）。然而，治疗后患者和对照组的中位值相似。与治疗前相比，患者治疗后 S100A8/A9 水平显著降低（P=.001）。在组内检查炎症标志物时，标志物之间未发现相关性。在 ROC 分析中，S100A8/A9 截断值≥3.31μg/mL 可准确区分治疗结束时的 PET 阳性（AUC=0.78；95%CI 0.58-0.98；准确性=76.2%）。